Based on the Actinium Pharmaceuticals Inc stock forecast from 6 analysts, the average analyst target price for Actinium Pharmaceuticals Inc is USD 15.14 over the next 12 months. Actinium Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Actinium Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Actinium Pharmaceuticals Inc’s stock price was USD 1.80. Actinium Pharmaceuticals Inc’s stock price has changed by +7.14% over the past week, -2.17% over the past month and +900.00% over the last year.
No recent analyst target price found for Actinium Pharmaceuticals Inc
No recent average analyst rating found for Actinium Pharmaceuticals Inc
Company Overview Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York. Address: 100 Park Avenue, New York, NY, United States, 10017 Read Less
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patie...Read More
Frequently Asked Questions About Actinium Pharmaceuticals Inc (ATNM) Stock
Based on ratings from 6 analysts Actinium Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ATNM's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ATNM is USD 15.14 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on ATNM's stock to indicate if its overvalued.
The last closing price of ATNM's stock was USD 1.80.
The most recent market capitalization for ATNM is USD 0.06B.
Based on targets from 6 analysts, the average taret price for ATNM is projected at USD 15.14 over the next 12 months.
This means that ATNM's stock price may go up by +741.27% over the next 12 months.
We can't find any ETFs which contains Actinium Pharmaceuticals Inc's stock.
As per our most recent records Actinium Pharmaceuticals Inc has 49 Employees.
Actinium Pharmaceuticals Inc's registered address is 100 Park Avenue, New York, NY, United States, 10017.
You can get more information about it from Actinium Pharmaceuticals Inc's website at https://www.actiniumpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Actinium Pharmaceuticals Inc (ATNM) Stock
Based on ratings from 6 analysts Actinium Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ATNM's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for ATNM is USD 15.14 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on ATNM's stock to indicate if its overvalued.
The last closing price of ATNM's stock was USD 1.80.
The most recent market capitalization for ATNM is USD 0.06B.
Based on targets from 6 analysts, the average taret price for ATNM is projected at USD 15.14 over the next 12 months.
This means that ATNM's stock price may go up by +741.27% over the next 12 months.
We can't find any ETFs which contains Actinium Pharmaceuticals Inc's stock.
As per our most recent records Actinium Pharmaceuticals Inc has 49 Employees.
Actinium Pharmaceuticals Inc's registered address is 100 Park Avenue, New York, NY, United States, 10017.
You can get more information about it from Actinium Pharmaceuticals Inc's website at https://www.actiniumpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATNM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
